Minneapolis, MN, Nov. 11, 2016 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing the PURE EP(TM) System, a novel cardiac electrophysiology (EP) signal acquisition and analysis system, today announced that its Chief Executive Officer, Mr. Gregory Cash will present at the Emerging Medical Technologies Summit. The Conference will be held today, November 11th 2016 in Redwood City, California. Event: Emerging Medical Technologies Summit Location: Pullman Hotel San Francisco Bay (Formerly The Sofitel) 223 Twin Dolphin Dr., Redwood City, CA Time: Friday, November 11th at 9:20 am During the conference, Mr. Cash will deliver the Company's corporate presentation and discuss recent business highlights. Management will also be available for one-on-one meetings. To arrange a meeting with management, please contact Lora Mikolaitis email@example.com. About BioSig Technologies BioSig Technologies is a medical device company that is developing a proprietary technology platform designed to improve the $4 billion EP marketplace (1) ( biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP System. The PURE EP(TM) System is a surface electrocardiogram and intracardiac multichannel signal acquisition and analysis system engineered to assist electrophysiologists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings and providing clarity of data which may be used to guide the electrophysiologists in identifying ablation targets - areas of tissue to treat that otherwise create a heart rhythm disturbance (arrhythmia). Analysts forecast the global market for EP devices will grow at a 12.1 percent compound annual growth rate, from $2.5 billion in 2012 to $5.5 billion by 2019(1), making it one of the fastest growing medical device segments. Just in the US, the number of Atrial Fibrillation (AF) and Ventricular Tachycardia (VT) arrhythmia ablations is forecast to grow at 10.5 percent from 2012 to 2017(2).